5,440 Shares in Lantheus Holdings, Inc. $LNTH Acquired by Savant Capital LLC

Posted by on Jun 6th, 2026

Savant Capital LLC purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,440 shares of the medical equipment provider’s stock, valued at approximately $362,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Intech Investment Management LLC grew its position in Lantheus by 28.2% in the fourth quarter. Intech Investment Management LLC now owns 81,221 shares of the medical equipment provider’s stock worth $5,405,000 after buying an additional 17,849 shares during the last quarter. Bleakley Financial Group LLC acquired a new position in Lantheus in the fourth quarter worth approximately $771,000. Harbour Investments Inc. grew its position in Lantheus by 6,775.0% in the fourth quarter. Harbour Investments Inc. now owns 1,375 shares of the medical equipment provider’s stock worth $92,000 after buying an additional 1,355 shares during the last quarter. Hantz Financial Services Inc. grew its position in Lantheus by 263.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,788 shares of the medical equipment provider’s stock worth $119,000 after buying an additional 1,296 shares during the last quarter. Finally, Covestor Ltd grew its position in Lantheus by 49.5% in the fourth quarter. Covestor Ltd now owns 2,602 shares of the medical equipment provider’s stock worth $173,000 after buying an additional 862 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Trading Down 1.8%

NASDAQ LNTH opened at $100.98 on Friday. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $104.00. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The stock has a market cap of $6.57 billion, a price-to-earnings ratio of 24.33 and a beta of -0.03. The firm’s 50 day moving average price is $88.01 and its two-hundred day moving average price is $74.96.

Lantheus (NASDAQ:LNTH – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same period in the previous year, the company posted $1.53 EPS. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts anticipate that Lantheus Holdings, Inc. will post 4.42 EPS for the current year.

Wall Street Analyst Weigh In

LNTH has been the topic of several recent research reports. Mizuho lifted their price target on shares of Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 27th. Citizens Jmp lifted their price target on shares of Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $110.00 price target on shares of Lantheus in a research report on Tuesday, March 17th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $101.86.

Check Out Our Latest Report on Lantheus

About Lantheus

(Free Report)

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Read More

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.